Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
← catalyst calendarNCT06723106 · readout in 558 d
Sponsored by Chugai Pharmaceutical (industry) · 4519.T — their whole pipeline →.
Phase
Phase 1
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
144estimated
Sites
62
Countries
Australia, Austria, Bulgaria +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-09 | actual | When the study began enrolling |
| Primary completion | 2028-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Antiphospholipid Syndrome (APS)
- Bullous Pemphigoid (BP)
- Behçet's Syndrome (BS)
- Dermatomyositis (DM)
- Immune-mediated Necrotizing Myopathy (IMNM)
- Immune Thrombocytopenia (ITP)
Intervention
- Drug: RAY121
Primary outcome
what the primary-completion date above is the date OFAdverse events (AEs)
measured Baseline to Week 52
Permalink · 4519.T's whole pipeline · Catalyst calendar · Every registered study · What changed